Reinventing clinical trials

被引：49

作者：

Allison, Malorye

机构：

[1] Malorye Allison is a freelance writer based in Acton,

[2] Massachusetts,undefined

[3] USA.,undefined

来源：

NATURE BIOTECHNOLOGY | 2012年 / 30卷 / 01期

关键词：

CANCER;

D O I：

10.1038/nbt.2083

中图分类号：

Q81 [生物工程学（生物技术）]; Q93 [微生物学];

学科分类号：

071005 ; 0836 ; 090102 ; 100705 ;

摘要：

As R&D costs spiral for drug developers, disruptive approaches to clinical trial design and management are gaining traction. Get ready for electronic data capture, precompetitive data sharing, virtual trials and a variety of bold new paradigms.

引用

页码：41 / 49

页数：9

共 25 条

[1] SPENDING ON NEW DRUG DEVELOPMENT [J].

Adams, Christopher Paul ;

Brantner, Van Vu .

HEALTH ECONOMICS, 2010, 19 (02) :130-141

[2] Biomarker-led adaptive trial blazes a trail in breast cancer [J].

Allison, Malorye .

NATURE BIOTECHNOLOGY, 2010, 28 (05) :383-384

[3] The HER2 testing conundrum [J].

Allison, Malorye .

NATURE BIOTECHNOLOGY, 2010, 28 (02) :117-119

[4]

[Anonymous], NAT BIOTECHNOL

[5]

[Anonymous], CUTTING EDGE

[6]

[Anonymous], 2006, WEALTH NETWORKS

[7]

[Anonymous], EC TIMES

[8] Phase II failures: 2008-2010 [J].

Arrowsmith, John .

NATURE REVIEWS DRUG DISCOVERY, 2011, 10 (05) :1-1

[9] TRIAL WATCH Phase III and submission failures: 2007-2010 [J].

Arrowsmith, John .

NATURE REVIEWS DRUG DISCOVERY, 2011, 10 (02) :1-1

[10]

DHHS Office of the Inspector General, 2001, GLOB CLIN TRIALS GRO

← 1 2 3 →